logo
logo

Lts Completes Its Entry Into Large Molecule Drug Delivery With The Acquisition Of The Sorrel Wearable Injection Device Business

Jun 08, 2023about 2 years ago

Acquiring Company

LTS

Acquired Company

Sorrel

JapanOil And Gas

Description

LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"), Oral Thin Films ("OTF") and Micro Array Patches ("MAP") has completed its acquisition of the Sorrel wearable injection device business ("Sorrel") with headquarters in Netanya, Israel, from Eitan Medical Ltd ("Eitan Medical"). Terms of the transaction, previously announced on April 20, were not disclosed.

Company Information

Company

LTS

Location

Japan

About

The company expects to continue expanding its size to 4,000 employees by 2025. The company has served over 1000+ customers worldwide, 85 of which are Fortune Global 500 companies in Aerospace & Aviation, Manufacturing & Automotive, Banking, Finance, Insurance, Logistics & Transportation, Healthcare & Life Sciences, Retail e-Commerce, Utilities & Energy, and more.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed